Week 07/03/2006 through 07/09/2006

Prepared by Capital Hunter analysts

As we cautioned last week, very little activity happened this reporting period, as only sixteen companies received venture capital financing totaling approximately $165 million, which under normal circumstances would be an abysmally low figure. The weekly venture capital activity chart below will have this period’s numbers but we will likely roll them up into the upcoming period’s numbers. In addition there are no IPOs to report, so this newsletter will be rather brief this week. Don’t be surprised if you see large numbers this upcoming week, as employees at firms that took the entire Fourth of July week off go through all of their backlogged work.

Please come visit our web site at CapitalHunter.com. We have made improvements to both the look and functionality of our web site, including business resources, glossary terms, and other helpful information provided free of charge for the budding entrepreneur. For private equity firms, consulting firms, business journals, and individuals looking to do research on venture backed companies, you can still gain complete access to our entire database for $59 a quarter and $199 a year.

CapitalHunter.com was able to verify that $165 million of venture capital was invested in 16 U.S.-based companies during the past week. The average deal size was approximately 10.31 million. The amount of venture capital invested this period decreased by 49% compared to last periods $326 million.

California was the largest recipient of venture capital funding this week. Eight California companies raised $96.4 million in new equity financing, which accounted for 58% of the total venture capital invested this reporting period. The largest private venture financing in California was placed into Ambrx. Ambrx raised $52 million in Series C funding and is a biopharmaceutical company committed to transforming the science and performance of protein-based medicines.

The biotechnology sector raised the most venture capital this reporting period, with four companies raising $79 million in venture financing, which accounted for 49% of the venture capital this period. The largest private venture financing in the biotechnology sector was also Ambrx.

Start-ups raising their Series C stages of financing represented the largest share of the funding pie, as a whopping 42% of all money invested this period went into such companies. The largest such financing was also placed into Ambrx.

The three largest venture deals this period are as follows:

The following twenty companies and other unnamed investors funded the above mentioned top three venture capital investments for $85 million:

A total of 35 equity financings of private and public companies occurred during this reporting period. Each of the 35 equity financings are profiled in a weekly (in this case biweekly) report which include venture financings, private placements, secondary offerings, PIPE’s, and IPO’s.

About CapitalHunter.com

CapitalHunter.com is a web-based financial information company that identifies, preserves and electronically disseminates worldwide data on venture capital and other equity financings. Customers utilize the CapitalHunter.com searchable database to research newly and historic financings and to identify active investors.

Please visit www.capitalhunter.com and get immediate access. New subscribers can request a free investor analysis.

To be REMOVED from this free service, CLICK HERE